Biotech ETF (XBI) Hits New 52-Week High
For investors seeking momentum, State Street SPDR S&P Biotech ETF XBI is probably on the radar. The fund just hit a 52-week high and rose 73.06% from its 52-week low price of $66.66/share.But, are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook to get…
For investors seeking momentum, State Street SPDR S&P Biotech ETF XBI is probably on the radar. The fund just hit a 52-week high and rose 73.06% from its 52-week low price of $66.66/share.But, are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook to get…
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
